Compare tirzepatide prices across every GPhC-registered UK pharmacy. All six doses from 2.5mg to 15mg. Verified weekly. No pharmacy pays to rank first.
MHRA approvedNICE TA1026tirzepatide · Eli LillyOnce weekly injection
~20%avg. weight loss at 72 wks
£149lowest price/month
11pharmacies tracked
GPhC-verified only No paid placements Updated April 2026
Prices by dose
Verified April 2026
Starting dose — most patients begin here for 4 weeks before titrating up.
Type:
Sort:
Pharmacy
Price / month
Trustpilot
Verified
Seen a cheaper price somewhere?
Spotted a lower price?
We verify all submissions and update our listings weekly. Your tip helps other patients save money.
Important: Private prescription only. Mounjaro is a prescription-only medicine — a clinical assessment is required before any pharmacy can supply it. Always verify pharmacy registration at pharmacyregulation.org.
About Mounjaro
How it works
Mounjaro contains tirzepatide, which acts on two hormonal receptors simultaneously — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Most other weight loss injections, including Wegovy and Saxenda, act on GLP-1 alone. This dual action is thought to explain why Mounjaro tends to produce greater average weight loss than single-agent GLP-1 drugs.
It works by slowing gastric emptying (making you feel full for longer), reducing appetite signals in the brain, and improving how the body processes blood sugar. You inject it once a week under the skin of your stomach, thigh, or upper arm using a pre-filled pen.
Clinical trial results
The SURMOUNT-1 trial, the pivotal study for tirzepatide in obesity, found that patients on the 15mg dose lost an average of 20.9% of body weight over 72 weeks when combined with lifestyle changes. Around 37% of participants lost 25% or more of their body weight. At the 5mg dose, average weight loss was around 15%. These figures come from controlled trial conditions — real-world results vary.
Doses and titration
Treatment always starts at 2.5mg weekly. The dose is increased by 2.5mg every four weeks, based on tolerability, up to a maximum of 15mg.
Who is it for?
Private prescription
BMI ≥ 30, or BMI ≥ 27 with a weight-related condition such as prediabetes, high blood pressure, high cholesterol or heart problems
Adults aged 18 and over
Not pregnant or planning pregnancy
No history of pancreatitis or medullary thyroid cancer
Not taking certain diabetes medications (check with prescriber)
Who should not take Mounjaro: people who are pregnant or planning to become pregnant, those breastfeeding, anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and those with a history of pancreatitis. If you take the contraceptive pill, additional contraception is recommended as Mounjaro may reduce its absorption.
Oral contraceptive pill and HRT:NHS England specifically warns that Mounjaro may reduce the effectiveness of the contraceptive pill. Use an additional method (such as condoms) for at least four weeks after each dose increase. If you are using oral HRT, speak to your prescriber — Mounjaro's effect on gastric emptying may affect absorption of some oral hormone preparations, and they may recommend switching to a transdermal form.
Side effects
Most side effects are gastrointestinal and occur at the start of treatment or after a dose increase. They typically settle within a few weeks as the body adjusts.
Nausea
Very common, especially in the first weeks. Usually mild and temporary.
Diarrhoea / constipation
Common. Staying well hydrated helps. Usually settles over time.
Vomiting
Common, particularly around dose increases. Eating smaller meals can help.
Fatigue
Reported by some patients, especially early in treatment.
Injection site reactions
Mild redness or discomfort where injected. Rotate injection sites.
Pancreatitis (rare)
Severe abdominal pain with or without vomiting — seek immediate medical help.
Hair loss is reported by some patients, typically linked to rapid weight loss rather than the medication itself. Full side effect information is listed in the Mounjaro patient information leaflet (EMC) included with your medication.
Frequently asked questions
Mounjaro (tirzepatide) acts on two hormone receptors — GLP-1 and GIP. Wegovy (semaglutide) acts on GLP-1 only. Clinical trials suggest Mounjaro produces greater average weight loss, though individual responses vary. Mounjaro is currently more expensive at most doses. Both require a prescription and a clinical assessment.
Yes, but access is very limited and phased. In year one (2025/26), NHS priority goes to adults with a BMI of 40 or above (or 37.5 for certain ethnic groups) who have four or more weight-related health conditions. The full eligible population of 3.4 million is expected to take up to 12 years to reach. GP participation varies by area — do not contact your GP proactively. Eligible patients are being contacted directly.
Most patients notice reduced appetite within the first few weeks. Meaningful weight loss typically becomes visible from around weeks 4–8. Clinical trials measured results at 72 weeks (about 18 months).
Evidence from the SURMOUNT-4 trial found that patients regained an average of 14% of their body weight within one year of stopping tirzepatide, even with continued lifestyle support. This reflects the underlying biology of obesity rather than a failure of willpower — the medication suppresses hunger signals that return when treatment stops. Most clinical guidelines treat Mounjaro as a long-term treatment rather than a short-term course.
Eli Lilly increased UK list prices for all Mounjaro KwikPen doses from 1 September 2025. The highest dose (15mg) rose to around £330, representing a significant increase. NHS reimbursement prices were redetermined by DHSC to match the new list prices. Private market prices set by individual pharmacies vary, which is why comparing across providers — as this site does — is particularly valuable post-increase.
Yes — they contain the same active ingredient (tirzepatide) at the same doses and work identically. Zepbound is the brand name used in the United States for the obesity indication; Mounjaro is used in the UK for both type 2 diabetes and obesity management. There is no clinical difference between the two.
NHS England and the MHRA advise using an additional method of contraception (such as condoms) while taking Mounjaro, because the medication may reduce how well the contraceptive pill is absorbed. This applies for at least four weeks after each dose increase. Discuss with your prescriber if you have specific questions about your contraception.
NHS access is phased and limited. Year 1 priority: BMI ≥ 40 with 4+ comorbidities. Full eligibility rollout is expected to take up to 12 years. Full NHS eligibility guide →